

September 4, 2009



## **XOMA to Present At Two Upcoming Investor Conferences**

BERKELEY, Calif., Sept. 4, 2009 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced that Steven Engle, Chairman and Chief Executive Officer, is scheduled to present at the following conferences in September 2009:

Rodman & Renshaw 11th Annual Healthcare Conference, New York City: September 10, 10:25 am EDT

BioCentury NewsMakers in the Biotech Industry Conference, New York City: September 16, 9:25 am EDT

Live and archived webcasts of these presentations will be available via the Investors tab of the XOMA website, [www.xoma.com](http://www.xoma.com).

### **About XOMA**

XOMA discovers, develops and manufactures antibody therapeutics designed to treat inflammatory, autoimmune, infectious and oncological diseases. The company's proprietary product pipeline includes XOMA 052, an anti-IL-1 beta antibody entering Phase 2 development, and XOMA 3AB, a biodefense anti-botulism antibody candidate.

XOMA has world-leading capabilities in antibody engineering and formulation, including a unique collection of antibody phage display libraries and expertise in the rapid construction of large novel libraries. Access to multiple libraries may offer a number of benefits to XOMA, its partners and licensees because it enables the use of libraries best suited to the needs of a particular discovery project. This increases the probability of technical and business success in finding rare and unique functional antibodies directed to targets of interest.

XOMA's proprietary technology platform also includes Targeted Affinity Enhancement(tm) for rapid, focused antibody affinity maturation, Human Engineering(tm) for antibody humanization and its widely-licensed bacterial cell expression and manufacturing technologies which have been licensed to more than 50 companies.

XOMA's multiple revenue streams result from the licensing of its antibody technologies, product royalties, development collaborations and biodefense contracts. XOMA's technologies team have contributed to the success of marketed antibody products, including LUCENTIS(r) (ranibizumab injection) for wet age-related macular degeneration and CIMZIA(r) (certolizumab pegol) for rheumatoid arthritis and Crohn's disease.

In addition to developing its own products, XOMA develops products with premier pharmaceutical companies including Schering-Plough Research Institute and Takeda Pharmaceutical Company Limited. XOMA has a fully integrated product development infrastructure, extending from pre-clinical science to approval, and a team of approximately 190 employees at its Berkeley, CA location. For more information, please visit <http://www.xoma.com>.

The XOMA Ltd. logo is available at <https://www.globenewswire.com/newsroom/prs/?pkgid=5960>

### Forward-Looking Statements

Certain statements contained herein relating to product development, or that otherwise relate to future periods, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on assumptions that may not prove accurate. Actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry and for companies engaged in the development of new products in a regulated market. These risks, including those related to the results of discovery research and preclinical testing; the timing or results of pending and future clinical trials (including the design and progress of clinical trials; safety and efficacy of the products being tested; action, inaction or delay by the FDA, European or other regulators or their advisory bodies; and analysis or interpretation by, or submission to, these entities or others of scientific data); uncertainties regarding the status of biotechnology patents; uncertainties as to the cost of protecting intellectual property; changes in the status of the existing collaborative and licensing relationships; the ability of collaborators, licensees and other third parties to meet their obligations; market demand for products; scale up and marketing capabilities; competition; international operations; share price volatility; XOMA's financing needs and opportunities; and risks associated with XOMA's status as a Bermuda company, are described in more detail in XOMA's most recent annual report on Form 10-K and in other SEC filings. Consider such risks carefully in considering XOMA's prospects.

CONTACT: XOMA Ltd.  
Carol DeGuzman  
510-204-7270  
[deguzman@xoma.com](mailto:deguzman@xoma.com)